INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo AKRINOR TABLETS
AKRINOR AMPOULES
SCHEDULING STATUS:
S1 - Tablets         S4 - Ampoules

PROPRIETARY NAME
(and dosage form):

AKRINOR TABLETS
AKRINOR AMPOULES

COMPOSITION:
Tablets:
Cafedrine HCl 100 mg
Theodrenaline HCl 5 mg
Ampoules: per 2 mL:
Cafedrine HCl 200 mg
Theodrenaline HCl 10 mg

PHARMACOLOGICAL CLASSIFICATION:
A.6.1. Cardiac stimulants.

PHARMACOLOGICAL ACTION:
Akrinor produces a reliable and sustained increase in blood pressure, the peripheral resistance remaining virtually unchanged. The effect on the blood pressure is obtained by an increase in stroke and minute volume. The heart rate is not increased. The oxygen supplied by the increased coronary blood flow significantly exceeds the oxygen requirements of the myocardium thus producing an improvement of the "quality of coronary blood flow". The prolonged effectiveness of AKRINOR is due to the properties of the active ingredients and not to a "depot effect" produced by ingredients added.

INDICATIONS:
All grades of circulatory weakness or circulatory collapse. Primary and secondary hypotension. Orthostatic hypotension.

CONTRA-INDICATIONS:
All hypersensitive conditions. Mitral stenosis. Glaucoma. Beta-blocking agent therapy.

DOSAGE AND DIRECTIONS FOR USE:
Tablets: The tablets are coated with a neutral protective film, and to avoid unpleasant taste, should be swallowed whole with some liquid.
Adults: One to two tablets once or twice daily. This dosage may be reduce after five to ten days.
Children: One tablet in the morning.

Ampoules:
Adults: Slow (1 mL per minite) intravenous injection of half to one ampoule according to the severity of the case, or one to five ampoules added to a 500 mL infusion solution. The intravenous injection should be reserved for acutely critical cases only.
Intramuscular injection: One ampoule once to several times daily.
Children:
  Infants up to 2 years:                0,2 to 0,4 mL
  Children 2 to 6 years:         0,4 to 0,6 mL
  Older children:         0,5 to 1,0 mL
  intramuscularly or intravenously as a single dose.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS
Palpitations. Anginal complaints may be intensified. Simultaneous intake of beta blocking agents may cause a major fall in heart rate.
Although there hve been no reports indicating an adverse effect of Akrinor during pregnancy, Akrinor, as with all other medicines should be administered with caution to pregnant women.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
No overdosage has been reported has been reported. Treatment should be symptomatic.

IDENTIFICATION
Tablets: White, biconvex film-coated tablet with an "A" on one side.
Ampoules: Clear, colourless solution in 2 mL clear ampoules.

PRESENTATION:
Tablet : 10, 30 and 100.
Ampoules : Clear, colourless solution in 2 mL clear ampoules.

STORAGE INSTRUCTIONS:
Store below 25°C.
KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER:
Tablet: G2904 (Act 101/1965)
Ampoules: G2903 (Act 101/1965)

NAME AND BUSINESS ADDRESS OF APPLICANT:
Adcock Ingram Ltd,
Adcock Ingram Park
17 Harrison Ave, Bryanston,
Private Bag X69, Bryanston,
2021

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
December 1998

New addition to this site: April 2004
Source: Pharmaceutical Industry

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2004